{
    "nctId": "NCT00971737",
    "briefTitle": "Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "A Randomized, Open-Label Comparative Study of Combination Therapy With Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer That Does NOT Over-express HER-2/Neu",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 63,
    "primaryOutcomeMeasure": "Toxicity as Assessed by Number of Grade 3 or 4 Adverse Events",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC\n  * Stage IV disease\n* Must not be eligible for therapy of known curative potential for metastatic breast cancer\n* Measurable or evaluable disease\n* Stable CNS disease allowed provided that it's adequately treated and not under active treatment\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-1\n* ANC \\> 1,000/mm\\^3\n* Platelets \\> 100,000/mm\\^3\n* Serum bilirubin \\< 2.0 mg/dL (unless due to Gilbert syndrome)\n* AST and ALT \\< 2 times upper limit of normal (ULN)\n* Alkaline phosphatase \\< 5 times ULN\n* Serum creatinine \\< 2.0 mg/dL\n* Ejection fraction normal by MUGA OR \u2265 50% by echocardiogram\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* HIV negative\n* Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed\n* No prior or concurrent autoimmune disease requiring management with systemic immunosuppression, including any of the following:\n\n  * Inflammatory bowel disease\n  * Systemic vasculitis\n  * Scleroderma\n  * Psoriasis\n  * Multiple sclerosis\n  * Hemolytic anemia or immune-mediated thrombocytopenia\n  * Rheumatoid arthritis\n  * Systemic lupus erythematosus\n  * Sjogren syndrome\n  * Sarcoidosis\n  * Other rheumatologic disease\n* No other malignancies within the past 5 years, except carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, superficial bladder cancer, or tamoxifen-related endometrial cancer that has been adequately treated\n* No active major medical or psychosocial problems that could be complicated by study participation\n* No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest\n* No uncontrolled medical problems\n* No evidence of active acute or chronic infection\n* No known severe hypersensitivity to trastuzumab, except mild to moderate infusion reactions that are easily managed and do not recur\n* No allergy to corn\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 28 days since prior and no other concurrent chemotherapy, radiation therapy, or biologic therapy (except trastuzumab)\n\n  * Concurrent endocrine therapy and supportive therapy with bisphosphonates allowed\n* More than 28 days since prior and no other concurrent participation in an investigational new drug trial\n* More than 28 days since prior and no other concurrent systemic oral steroids\n\n  * Topical, ocular, and nasal steroids allowed\n* No prior vaccination with the allogeneic GM-CSF-secreting breast tumor vaccine",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}